NICE accepts golimumab for psoriatic arthritis

Up to 30% of people with psoriasis develop psoriatic arthritis
Up to 30% of people with psoriasis develop psoriatic arthritis

Golimumab (Simponi) has been recommended by NICE as an option in the treatment of psoriatic arthritis. It can be used in the same circumstances as the other tumour necrosis factor (TNF) inhibitor treatments (etanercept, infliximab and adalimumab) for this condition.

Specifically, golimumab may be used in adults with active and progressive psoriatic arthritis with 3 or more tender joints and 3 or more swollen joints when treatment with at least 2 DMARDs has failed. NICE has also stipulated that the manufacturer must provide the 100mg dose of golimumab for patients who weigh over 100kg at the same cost as the 50mg dose.

Treatment should normally be started with the least expensive TNF inhibitor, and should be stopped if response is not adequate at 12 weeks, as determined by the Psoriatic Arthritis Response Criteria (PsARC).

View Simponi drug record

Further Information: Merck Sharp & Dohme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases